SOLUTION / PUBLIC SOURCE RECORD
Ledidi secure platform for health research and clinical trials
- Published July 1, 2025; updated March 23, 2026; estimated reading time 3 minutes. Status: available across the Americas, Europe, Asia, Africa and Oceania. Category: Health and life science / Digital health.
- Ledidi’s cloud platform combines health-data collection, analysis, visualization and real-time collaboration for research projects, clinical registries and clinical trials. It is designed for privacy by default and cites compliance with GDPR and HIPAA plus ISO 27001, SOC 2 and Cyber Essentials certifications. Access permissions can be assigned by role; researchers can analyze aggregate insights without exposing raw personal data.
- The page says clinicians, researchers and administrators can streamline workflows, reduce manual work, and gain insights faster for small projects or multicenter studies. Replacing disconnected tools with one platform is intended to lower operating costs. Cloud operation and digital workflows may also reduce physical infrastructure and paper use.
- The article describes the challenge of balancing privacy protections with sharing data for research, including Norwegian researchers’ difficulty accessing health data. It identifies hospitals, universities, medical societies, medtech, biotech, pharmaceutical firms and public-health institutions as target customers. The platform is described as commercially available and supporting research, registries and trials globally.
- The page cites the global clinical-trials market at USD 80.7 billion in 2023, forecast to reach USD 123.5 billion by 2030. It links an interview with Ledidi’s CEO, two customer case studies (including a Central Norway myeloma registry), and a testimonial from Dr John Goodden, Consultant Neurosurgeon at Leeds Teaching Hospitals NHS Trust. SDG 3 shown.
- Contact: Kent Jordet, Chief Revenue Officer, kent.jordet@ledidi.com; phone reveal control collapsed. Company: LEDIDI AS, Gaustadalléen 21, 0349 Oslo, Norway; ledidi.com.